Clinical Trial Update: A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

View source ↗

Summary

AstraZeneca-conducted, non-interventional study completed, surveying EGFR mutation status in Chinese patients with completely resected non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Status: COMPLETED